Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00029731 · ClinicalTrials.gov registry record · Phase 2
Arginine Treatment of Acute Chest Syndrome (Pneumonia) in Sickle Cell Disease Patients
A Phase 2 study, sponsored by UCSF Benioff Children's Hospital Oakland.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00029731: Completed Phase 2 study, sponsored by UCSF Benioff Children's Hospital Oakland.
NCT00029731 is a Phase 2 study that has completed, run by UCSF Benioff Children's Hospital Oakland. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00029731, a Phase 2 study, has completed, sponsored by UCSF Benioff Children's Hospital Oakland.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a study to determine if oral arginine will increase nitric oxide in sickle cell disease (SCD) patients with acute chest syndrome (ACS). It will also assess the effects of arginine in the body and how the body uses nitric oxide in ACS.
Interventions
- DRUG Arginine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2001-08 |
| Est. Completion | 2005-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00029731
The ClinicalTrials.gov registry entry for NCT00029731 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCSF Benioff Children's Hospital Oakland, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Arginine hydrochloride is the first listed.
NCT00029731 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00029731 about?
NCT00029731 is a clinical study titled "Arginine Treatment of Acute Chest Syndrome (Pneumonia) in Sickle Cell Disease Patients". This is a study to determine if oral arginine will increase nitric oxide in sickle cell disease (SCD) patients with acute chest syndrome (ACS). It will also assess the effects of arginine in the body and how the body uses nitric oxide in ACS.
What is the current status of trial NCT00029731?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2001-08. Estimated completion is 2005-07.
What interventions are being tested in trial NCT00029731?
The interventions under investigation include: Arginine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00029731?
This trial is sponsored by UCSF Benioff Children's Hospital Oakland, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.